Form 8-K

8-K — JOHNSON & JOHNSON

Accession: 0000200406-26-000076

Filed: 2026-04-14

Period: 2026-04-14

CIK: 0000200406

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — jnj-20260414.htm (Primary)

EX-99.1 (a2026q1exhibit991.htm)

EX-99.2 (a2026q1exhibit992.htm)

EX-99.3 (a2026q1exhibit993.htm)

GRAPHIC (image_0.jpg)

GRAPHIC (image_1a.jpg)

GRAPHIC (jnjlogoa.jpg)

GRAPHIC (jnjlogob.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: jnj-20260414.htm · Sequence: 1

jnj-20260414

0000200406false00002004062026-04-142026-04-140000200406us-gaap:CommonStockMember2026-04-142026-04-140000200406jnj:A1.150NotesDueNovember2028Member2026-04-142026-04-140000200406jnj:A2.700NotesDueFebruary2029Member2026-04-142026-04-140000200406jnj:A3.20NotesDueJune2032Member2026-04-142026-04-140000200406jnj:A3.050NotesDueFebruary2033Member2026-04-142026-04-140000200406jnj:A1.650NotesDueMay2035Member2026-04-142026-04-140000200406jnj:A3.350NotesDueJune2036Member2026-04-142026-04-140000200406jnj:A3.350NotesDueFebruary2037Member2026-04-142026-04-140000200406jnj:A3.550NotesDueJune2044Member2026-04-142026-04-140000200406jnj:A3.600NotesDueFebruary2045Member2026-04-142026-04-140000200406jnj:A3.700NotesDueFebruary2055Member2026-04-142026-04-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

April 14, 2026

Johnson & Johnson

(Exact name of registrant as specified in its charter)

New Jersey

1-3215

22-1024240

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $1.00

JNJ

New York Stock Exchange

1.150% Notes Due November 2028

JNJ28

New York Stock Exchange

2.700% Notes Due February 2029

JNJ29B

New York Stock Exchange

3.200% Notes Due June 2032

JNJ32

New York Stock Exchange

3.050% Notes Due February 2033

JNJ33B

New York Stock Exchange

1.650% Notes Due May 2035

JNJ35

New York Stock Exchange

3.350% Notes Due June 2036

JNJ36A

New York Stock Exchange

3.350% Notes Due February 2037

JNJ37B

New York Stock Exchange

3.550% Notes Due June 2044

JNJ44

New York Stock Exchange

3.600% Notes Due February 2045

JNJ45

New York Stock Exchange

3.700% Notes Due February 2055

JNJ55

New York Stock Exchange

Item 2.02 Results of operations and financial condition

On April 14, 2026, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 29, 2026.

Item 8.01 Other Events

On April 14, 2026, Johnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026.

Item 9.01 Financial statements and exhibits

(d) Exhibits.

Exhibit No. Description of Exhibit

99.1

Press Release dated April 14, 2026 for the period ended March 29, 2026

99.2

Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal first quarter

99.3

Press Release dated April 14, 2026

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 14, 2026

JOHNSON & JOHNSON

(Registrant)

By:

/s/ Robert J. Decker, Jr.

Robert J. Decker, Jr.

Controller

(Principal Accounting Officer)

EX-99.1

Filename: a2026q1exhibit991.htm · Sequence: 2

Document

Exhibit 99.1

Media contact:

media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

For immediate release

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

•2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%*

•2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70

•Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint

•Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIPULSE Pro in Europe with a new pulse sequence that is now 5 times faster, and TECNIS PureSee Intraocular Lens for U.S. Cataract Patients

•Company announces planned Enterprise Business Review for December 8, 2026

New Brunswick, N.J. (April 14, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2026. “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders.”

Overall financial results

($ in Millions, except EPS)

2026

2025

% Change

Reported Sales

$24,062

$21,893

9.9%

Net Earnings

$5,235

$10,999

-52.4%

EPS (diluted)

$2.14

$4.54

-52.9%

Non-GAAP* ($ in Millions, except EPS)

2026

2025

% Change

Operational Sales1,2

6.4%

Adjusted Operational Sales1,3

5.3%

Adjusted Net Earnings1,4

$6,614

$6,706

-1.4%

Adjusted EPS (diluted)1,4

$2.70

$2.77

-2.5%

Free Cash Flow5,6

~$1,500

$3,379

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

4Excludes intangible amortization expense and special items

5Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

6First-quarter 2026 is estimated as of April 14, 2026

Note: values may have been rounded

Regional sales results

% Change

($ in Millions)

2026

2025

Reported

Operational1,2

Currency

Adjusted

Operational1,3

U.S.

$13,330

$12,305

8.3%

8.3

6.2

International

10,732

9,588

11.9

3.9

8.0

4.0

Worldwide

$24,062

$21,893

9.9%

6.4

3.5

5.3

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Segment sales results

% Change

($ in Millions)

2026

2025

Reported

Operational1,2

Currency

Adjusted

Operational1,3

Innovative Medicine

$15,426

$13,873

11.2%

7.4

3.8

5.6

MedTech

8,636

8,020

7.7

4.6

3.1

4.7

Worldwide

$24,062

$21,893

9.9%

6.4

3.5

5.3

1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2Excludes the impact of translational currency

3Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

First-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 7.4%*, with net acquisitions and divestitures positively impacting growth by 1.8% primarily due to CAPLYTA. Growth was driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (920) basis points impact from STELARA in Immunology, as well as IMBRUVICA in Oncology.

MedTech

MedTech worldwide operational sales grew 4.6%*, with divestitures negatively impacting growth by 0.1%. Growth was driven primarily by electrophysiology products, Abiomed, and Shockwave in Cardiovascular, as well as trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

April 2026

January 2026

Adjusted Operational Sales1,2

Change vs. Prior Year / Mid-point

5.6% – 6.6% / 6.1%

5.4% – 6.4% / 5.9%

Operational Sales2 / Mid-point

Change vs. Prior Year / Mid-point

$99.7B – $100.7B / $100.2B

5.9% – 6.9% / 6.4%

$99.5B – $100.5B / $100.0B

5.7% – 6.7% / 6.2%

Estimated Reported Sales3/ Mid-point

Change vs. Prior Year / Mid-point

$100.3B – $101.3B / $100.8B

6.5% – 7.5% / 7.0%

$100.0B – $101.0B / $100.5B

6.2% – 7.2% / 6.7%

Adjusted Operational EPS (Diluted)2,4 / Mid-point

Change vs. Prior Year / Mid-point

$11.30 – $11.50 / $11.40

4.7% – 6.7% / 5.7%

$11.28 – $11.48 / $11.38

4.5% – 6.5% / 5.5%

Adjusted EPS (Diluted)3,4 / Mid-point

Change vs. Prior Year / Mid-point

$11.45 – $11.65 / $11.55

6.1% – 8.1% / 7.1%

$11.43 – $11.63 / $11.53

5.9% – 7.9% / 6.9%

1Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2Non-GAAP financial measure; excludes the impact of translational currency

3Calculated using Euro Average Rate: April 2026 = $1.17 and January 2026 = $1.17 (Illustrative purposes only)

4Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com.

Regulatory

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Press Release

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Press Release

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Press Release

Johnson & Johnson seeks FDA approval of IMAAVY (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Press Release

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Press Release

FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Press Release

DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Press Release

Data Releases

Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 20261

Press Release

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision1

Press Release

STEMI DTU Randomized Control Trial Demonstrates for the First Time that a Combination of Delayed Reperfusion and Left Ventricular Unloading Does Not Increase Myocardial Infarct Size

Press Release

ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Press Release

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Press Release

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Press Release

TREMFYA (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Press Release

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Press Release

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Press Release

Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA (apalutamide) versus darolutamide without docetaxel through 24 months

Press Release

Product Launch

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe1

Press Release

FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Press Release

Other

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Press Release

1Subsequent to the quarter

Webcast information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

Non-GAAP financial measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

Note to investors concerning forward-looking statements:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

EX-99.2

Filename: a2026q1exhibit992.htm · Sequence: 3

Document

Exhibit 99.2

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) FIRST QUARTER

Percent Change

Sales to customers by geographic area 2026 2025 Total Operations Currency

U.S.

$13,330 12,305 8.3 % 8.3 —

Europe

5,848 5,110 14.5 2.7 11.8

Western Hemisphere excluding U.S.

1,293 1,167 10.8 2.5 8.3

Asia-Pacific, Africa

3,591 3,311 8.5 6.1 2.4

International

10,732 9,588 11.9 3.9 8.0

Worldwide

$24,062 21,893 9.9 % 6.4 3.5

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions) FIRST QUARTER

Percent Change

Sales to customers by segment of business 2026 2025 Total Operations Currency

Innovative Medicine

U.S.

$ 8,871 8,092 9.6 % 9.6 —

International

6,555 5,781 13.4 4.3 9.1

15,426 13,873 11.2 7.4 3.8

MedTech

U.S.

4,459 4,213 5.9 5.9 —

International

4,177 3,807 9.7 3.2 6.5

8,636 8,020 7.7 4.6 3.1

U.S.

13,330 12,305 8.3 8.3 —

International

10,732 9,588 11.9 3.9 8.0

Worldwide

$ 24,062 21,893 9.9 % 6.4 3.5

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures) FIRST QUARTER

2026 2025 Percent

Increase

(Decrease)

Amount Percent

to Sales Amount Percent

to Sales

Sales to customers $ 24,062 100.0 $ 21,893 100.0 9.9

Cost of products sold 8,106 33.7 7,357 33.6 10.2

Gross Profit 15,956 66.3 14,536 66.4 9.8

Selling, marketing and administrative expenses 6,034 25.1 5,112 23.3 18.0

Research and development expense 3,527 14.7 3,225 14.7 9.4

In-process research and development impairments 36 0.1 — —

Interest (income) expense, net 43 0.2 (128) (0.6)

Other (income) expense, net 294 1.2 (7,321) (33.4)

Restructuring 32 0.1 17 0.1

Earnings before provision for taxes on income 5,990 24.9 13,631 62.3 (56.1)

Provision for taxes on income 755 3.1 2,632 12.1 (71.3)

Net earnings $ 5,235 21.8 $ 10,999 50.2 (52.4)

Net earnings per share (Diluted) $ 2.14 $ 4.54 (52.9)

Average shares outstanding (Diluted) 2,445.2 2,423.8

Effective tax rate 12.6 % 19.3 %

Adjusted earnings before provision for taxes and net earnings (1) (A)

Earnings before provision for taxes on income

$ 7,821 32.5 $ 8,011 36.6 (2.4)

Net earnings

$ 6,614 27.5 $ 6,706 30.6 (1.4)

Net earnings per share (Diluted)

$ 2.70

$ 2.77

(2.5)

Effective tax rate

15.4 %

16.3 %

(1) See Reconciliation of Non-GAAP Financial Measures.

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

First Quarter

(Dollars in Millions Except Per Share Data) 2026 2025

Net Earnings, after tax- as reported $5,235 $10,999

Pre-tax Adjustments

Intangible Asset Amortization expense 1,247 1,120

Litigation related 330 (6,966)

Orthopaedics Separation related 119 —

Acquisition, integration and divestiture related 96 132

Restructuring related 1

62 55

IPR&D impairments 36 —

(Gains)/losses on securities (59) 39

Tax Adjustments

Tax impact on special item adjustments 2

(424) 1,315

Tax legislation and other tax related (28) 12

Adjusted Net Earnings, after tax $6,614 $6,706

Average shares outstanding (Diluted) 2,445.2 2,423.8

Adjusted net earnings per share (Diluted) $2.70 $2.77

Operational adjusted net earnings per share (Diluted) $2.57

Notes:

1In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $7 million in the fiscal first quarter of 2026 and $55 million in the fiscal first quarter of 2025 primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $55 million in the fiscal first quarter of 2026 primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

First quarter 2026 actual vs. 2025 actual

Segments

Innovative Medicine MedTech Total

WW As Reported 11.2 % 7.7 % 9.9 %

U.S. 9.6 % 5.9 % 8.3 %

International 13.4 % 9.7 % 11.9 %

WW Currency 3.8 3.1 3.5

U.S. — — —

International 9.1 6.5 8.0

WW Operational 7.4 % 4.6 % 6.4 %

U.S. 9.6 % 5.9 % 8.3 %

International 4.3 % 3.2 % 3.9 %

Caplyta (1.9) (1.2)

U.S. (3.3) (2.2)

International 0.0 0.0

All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1

U.S. 0.0 0.2 0.1

International 0.2 0.0 0.1

WW Adjusted Operational Ex A&D 5.6 % 4.7 % 5.3 %

U.S. 6.3 % 6.1 % 6.2 %

International 4.5 % 3.2 % 4.0 %

Note: Percentages are based on actual, non-rounded figures and may not sum

(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

Johnson & Johnson

Segment sales

(Dollars in Millions)

FIRST QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)

ONCOLOGY

US $3,615 3,013 20.0 % 20.0 % — %

Intl 3,358 2,664 26.0 15.3 10.7

WW 6,973 5,678 22.8 17.8 5.0

DARZALEX

US 2,208 1,829 20.7 20.7 —

Intl 1,756 1,409 24.7 14.0 10.7

WW 3,964 3,237 22.5 17.8 4.7

CARVYKTI

US 433 318 36.2 36.2 —

Intl 164 51 * * *

WW 597 369 62.1 57.4 4.7

TECVAYLI

US 127 105 20.6 20.6 —

Intl 74 46 63.1 52.1 11.0

WW 202 151 33.5 30.1 3.4

TALVEY

US 101 68 48.5 48.5 —

Intl 51 18 * * *

WW 152 86 76.7 72.8 3.9

RYBREVANT / LAZCLUZE

US 175 113 55.1 55.1 —

Intl 82 28 * * *

WW 257 141 82.7 80.5 2.2

ERLEADA

US 342 292 17.3 17.3 —

Intl 607 479 26.7 15.5 11.2

WW 949 771 23.1 16.2 6.9

IMBRUVICA

US 143 235 (39.1) (39.1) —

Intl 517 474 9.1 (1.4) 10.5

WW 660 709 (6.9) (13.9) 7.0

OTHER ONCOLOGY(3)

US 85 54 58.8 58.8 —

Intl 106 160 (33.9) (36.3) 2.4

WW 192 214 (10.6) (12.5) 1.9

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

FIRST QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

IMMUNOLOGY

US $1,855 2,196 (15.5) % (15.5) % — %

Intl 1,524 1,510 0.9 (6.4) 7.3

WW 3,380 3,707 (8.8) (11.8) 3.0

TREMFYA

US 1,042 599 73.9 73.9 —

Intl 566 356 58.9 46.8 12.1

WW 1,608 956 68.3 63.8 4.5

SIMPONI / SIMPONI ARIA

US 269 292 (7.8) (7.8) —

Intl 378 366 3.0 (4.1) 7.1

WW 647 659 (1.7) (5.7) 4.0

REMICADE

US 269 314 (14.4) (14.4) —

US Exports(4)

18 10 78.6 78.6 —

Intl 136 143 (4.8) (10.5) 5.7

WW 422 467 (9.5) (11.2) 1.7

STELARA

US 220 981 (77.6) (77.6) —

Intl 435 644 (32.4) (37.7) 5.3

WW 656 1,625 (59.7) (61.7) 2.0

OTHER IMMUNOLOGY

US 38 1 * * —

Intl 9 0 * * *

WW 46 1 * * *

NEUROSCIENCE

US 1,494 968 54.3 54.3 —

Intl 681 679 0.3 (6.3) 6.6

WW 2,175 1,647 32.0 29.3 2.7

SPRAVATO

US 406 276 47.0 47.0 —

Intl 61 43 42.4 28.7 13.7

WW 468 320 46.4 44.5 1.9

CAPLYTA(5)

US 270 — * * —

Intl — — — — —

WW 270 — * * —

INVEGA SUSTENNA / XEPLION / INVEGA

TRINZA / TREVICTA

US 758 625 21.2 21.2 —

Intl 280 277 1.1 (4.9) 6.0

WW 1,038 903 15.0 13.2 1.8

CONCERTA / methylphenidate

US 22 38 (43.4) (43.4) —

Intl 115 110 4.3 (0.6) 4.9

WW 136 148 (8.0) (11.7) 3.7

OTHER NEUROSCIENCE

US 38 28 32.6 32.6 —

Intl 224 248 (9.7) (16.3) 6.6

WW 262 277 (5.4) (11.3) 5.9

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

FIRST QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

PULMONARY HYPERTENSION (PH)

US $831 744 11.7 % 11.7 % — %

Intl 304 281 8.2 1.0 7.2

WW 1,135 1,025 10.7 8.7 2.0

UPTRAVI

US 385 365 5.4 5.4 —

Intl 98 86 14.3 5.1 9.2

WW 483 451 7.1 5.4 1.7

OPSUMIT / OPSYNVI

US 433 363 19.3 19.3 —

Intl 172 159 8.7 1.7 7.0

WW 606 522 16.1 14.0 2.1

OTHER PULMONARY HYPERTENSION

US 12 15 (21.1) (21.1) —

Intl 34 37 (8.3) (11.8) 3.5

WW 46 52 (12.1) (14.5) 2.4

INFECTIOUS DISEASES (ID)

US 342 315 8.6 8.6 —

Intl 547 487 12.2 1.3 10.9

WW 889 802 10.8 4.1 6.7

EDURANT / rilpivirine

US 7 8 (13.1) (13.1) —

Intl 402 350 14.8 3.2 11.6

WW 409 358 14.1 2.8 11.3

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US 334 305 9.5 9.5 —

Intl 109 98 11.2 0.7 10.5

WW 443 403 10.0 7.4 2.6

OTHER INFECTIOUS DISEASES

US 1 2 (56.9) (56.9) —

Intl 36 39 (8.3) (14.7) 6.4

WW 37 41 (10.4) (16.5) 6.1

CARDIOVASCULAR / METABOLISM / OTHER (CVM)

US 734 855 (14.2) (14.2) —

Intl 142 158 (10.4) (17.5) 7.1

WW 876 1,013 (13.6) (14.7) 1.1

XARELTO

US 642 690 (7.0) (7.0) —

Intl — — — — —

WW 642 690 (7.0) (7.0) —

OTHER

US 91 165 (44.5) (44.5) —

Intl 142 158 (10.4) (17.5) 7.1

WW 233 323 (27.8) (31.2) 3.4

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

FIRST QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

INNOVATIVE MEDICINE SEGMENT(2)(Continued)

TOTAL PH, ID, CVM

US 1,907 1,914

(0.4) (0.4) —

Intl 993 926

7.1 (2.0) 9.1

WW 2,899 2,840 2.1 (0.9) 3.0

TOTAL INNOVATIVE MEDICINE

US 8,871 8,092 9.6 9.6 —

Intl 6,555 5,781 13.4 4.3 9.1

WW $15,426 13,873 11.2 % 7.4 % 3.8 %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

FIRST QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)

CARDIOVASCULAR

US $1,399 1,261 10.9 % 10.9 % — %

Intl 978 842 16.1 9.9 6.2

WW 2,377 2,103 13.0 10.5 2.5

ELECTROPHYSIOLOGY

US 736 684 7.6 7.6 —

Intl 753 638 18.0 11.7 6.3

WW 1,489 1,323 12.6 9.5 3.1

ABIOMED

US 389 339 14.5 14.5 —

Intl 100 81 23.5 13.9 9.6

WW 488 420 16.3 14.4 1.9

SHOCKWAVE

US 242 206 17.8 17.8 —

Intl 63 52 21.3 19.3 2.0

WW 305 258 18.5 18.1 0.4

OTHER CARDIOVASCULAR

US 32 32 0.7 0.7 —

Intl 62 72 (13.4) (17.5) 4.1

WW 94 103 (9.1) (11.9) 2.8

SURGERY

US 1,046 1,002 4.4 4.4 —

Intl 1,465 1,394 5.1 (1.1) 6.2

WW 2,511 2,396 4.8 1.2 3.6

ADVANCED

US 477 457 4.2 4.2 —

Intl 646 616 4.9 (1.0) 5.9

WW 1,123 1,073 4.6 1.2 3.4

GENERAL

US 569 544 4.5 4.5 —

Intl 819 778 5.2 (1.3) 6.5

WW 1,388 1,323 4.9 1.1 3.8

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

FIRST QUARTER

% Change

2026 2025 Reported

Operational(1)

Currency

MEDTECH SEGMENT(2)(Continued)

VISION

US $579 566 2.4 % 2.4 % — %

Intl 785 713 10.1 4.6 5.5

WW 1,365 1,279 6.7 3.6 3.1

CONTACT LENSES / OTHER

US 468 452 3.7 3.7 —

Intl 501 467 7.2 1.7 5.5

WW 969 919 5.5 2.7 2.8

SURGICAL

US 111 114 (2.9) (2.9) —

Intl 285 246 15.6 10.1 5.5

WW 396 361 9.7 6.0 3.7

ORTHOPAEDICS

US 1,435 1,384 3.7 3.7 —

Intl 948 857 10.6 2.4 8.2

WW 2,383 2,241 6.3 3.2 3.1

HIPS

US 277 263 5.2 5.2 —

Intl 159 146 8.9 0.3 8.6

WW 436 409 6.5 3.5 3.0

KNEES

US 239 231 3.3 3.3 —

Intl 181 158 14.6 6.5 8.1

WW 420 389 7.9 4.6 3.3

TRAUMA

US 532 502 6.1 6.1 —

Intl 301 270 11.4 3.1 8.3

WW 833 772 8.0 5.0 3.0

SPINE, SPORTS & OTHER

US 387 388 (0.1) (0.1) —

Intl 307 283 8.4 0.7 7.7

WW 694 671 3.5 0.2 3.3

TOTAL MEDTECH

US 4,459 4,213 5.9 5.9 —

Intl 4,177 3,807 9.7 3.2 6.5

WW $8,636 8,020 7.7 % 4.6 % 3.1 %

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1)Operational growth excludes the effect of translational currency

(2)Unaudited

(3)Includes the sales of ZYTIGA which were previously disclosed separately

(4)Reported as U.S. sales

(5)Acquired with Intra-Cellular Therapies on April 2, 2025

EX-99.3

Filename: a2026q1exhibit993.htm · Sequence: 4

Document

Exhibit 99.3

Media contact:

media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

For immediate release

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

New Brunswick, NJ (April 14, 2026) – Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases.

At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026.

About Johnson & Johnson

GRAPHIC

Filename: image_0.jpg · Sequence: 9

Binary file (244 bytes)

Download image_0.jpg

GRAPHIC

Filename: image_1a.jpg · Sequence: 10

Binary file (339 bytes)

Download image_1a.jpg

GRAPHIC

Filename: jnjlogoa.jpg · Sequence: 11

Binary file (2962 bytes)

Download jnjlogoa.jpg

GRAPHIC

Filename: jnjlogob.jpg · Sequence: 12

Binary file (2962 bytes)

Download jnjlogob.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 14

v3.26.1

Cover

Apr. 14, 2026

Cover [Abstract]

Document Period End Date

Apr. 14, 2026

Document Type

8-K

Entity Registrant Name

Johnson & Johnson

Entity Incorporation, State or Country Code

Entity File Number

1-3215

Entity Tax Identification Number

22-1024240

Entity Address, Address Line One

One Johnson & Johnson Plaza

Entity Address, City or Town

New Brunswick

Entity Address, State or Province

Entity Address, Postal Zip Code

08933

City Area Code

732

Local Phone Number

524-0400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Document Information [Line Items]

Entity Emerging Growth Company

false

Entity Central Index Key

0000200406

Amendment Flag

false

Common Stock

Cover [Abstract]

Title of 12(b) Security

Common Stock, Par Value $1.00

Document Information [Line Items]

Title of 12(b) Security

Common Stock, Par Value $1.00

Trading Symbol

JNJ

Security Exchange Name

NYSE

Trading Symbol

JNJ

Security Exchange Name

NYSE

1.150% Notes Due November 2028

Cover [Abstract]

Title of 12(b) Security

1.150% Notes Due November 2028

Document Information [Line Items]

Title of 12(b) Security

1.150% Notes Due November 2028

Trading Symbol

JNJ28

Security Exchange Name

NYSE

Trading Symbol

JNJ28

Security Exchange Name

NYSE

1.650% Notes Due 2035

Cover [Abstract]

Title of 12(b) Security

1.650% Notes Due May 2035

Document Information [Line Items]

Title of 12(b) Security

1.650% Notes Due May 2035

Trading Symbol

JNJ35

Security Exchange Name

NYSE

Trading Symbol

JNJ35

Security Exchange Name

NYSE

3.20% Notes Due June 2032

Cover [Abstract]

Title of 12(b) Security

3.200% Notes Due June 2032

Document Information [Line Items]

Title of 12(b) Security

3.200% Notes Due June 2032

Trading Symbol

JNJ32

Security Exchange Name

NYSE

Trading Symbol

JNJ32

Security Exchange Name

NYSE

3.350% Notes Due June 2036

Cover [Abstract]

Title of 12(b) Security

3.350% Notes Due June 2036

Document Information [Line Items]

Title of 12(b) Security

3.350% Notes Due June 2036

Trading Symbol

JNJ36A

Security Exchange Name

NYSE

Trading Symbol

JNJ36A

Security Exchange Name

NYSE

3.550% Notes Due June 2044

Cover [Abstract]

Title of 12(b) Security

3.550% Notes Due June 2044

Document Information [Line Items]

Title of 12(b) Security

3.550% Notes Due June 2044

Trading Symbol

JNJ44

Security Exchange Name

NYSE

Trading Symbol

JNJ44

Security Exchange Name

NYSE

2.700% Notes due February 2029

Cover [Abstract]

Title of 12(b) Security

2.700% Notes Due February 2029

Document Information [Line Items]

Title of 12(b) Security

2.700% Notes Due February 2029

Trading Symbol

JNJ29B

Security Exchange Name

NYSE

Trading Symbol

JNJ29B

Security Exchange Name

NYSE

3.050% Notes due February 2033

Cover [Abstract]

Title of 12(b) Security

3.050% Notes Due February 2033

Document Information [Line Items]

Title of 12(b) Security

3.050% Notes Due February 2033

Trading Symbol

JNJ33B

Security Exchange Name

NYSE

Trading Symbol

JNJ33B

Security Exchange Name

NYSE

3.350% Notes due February 2037

Cover [Abstract]

Title of 12(b) Security

3.350% Notes Due February 2037

Document Information [Line Items]

Title of 12(b) Security

3.350% Notes Due February 2037

Trading Symbol

JNJ37B

Security Exchange Name

NYSE

Trading Symbol

JNJ37B

Security Exchange Name

NYSE

3.600% Notes due February 2045

Cover [Abstract]

Title of 12(b) Security

3.600% Notes Due February 2045

Document Information [Line Items]

Title of 12(b) Security

3.600% Notes Due February 2045

Trading Symbol

JNJ45

Security Exchange Name

NYSE

Trading Symbol

JNJ45

Security Exchange Name

NYSE

3.700% Notes due February 2055

Cover [Abstract]

Title of 12(b) Security

3.700% Notes Due February 2055

Document Information [Line Items]

Title of 12(b) Security

3.700% Notes Due February 2055

Trading Symbol

JNJ55

Security Exchange Name

NYSE

Trading Symbol

JNJ55

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDueMay2035Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueJune2032Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueJune2036Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueJune2044Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A2.700NotesDueFebruary2029Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.050NotesDueFebruary2033Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueFebruary2037Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.600NotesDueFebruary2045Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=jnj_A3.700NotesDueFebruary2055Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: